A phase II, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280a (Anti-PD-L1 Antibody) compared with docetaxel in patients with Non-Small Cell Lung Cancer after platinum failure
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest